28 research outputs found
Π₯Π°ΡΠ°ΠΊΡΠ΅Ρ ΠΊΠ»ΠΈΠ½ΠΈΡΠ΅ΡΠΊΠΈΡ ΠΏΡΠΎΡΠ²Π»Π΅Π½ΠΈΠΉ ΠΎΠΆΠΎΠ³ΠΎΠ² Π³Π»Π°Π· Ρ ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΎΠ² Ρ ΡΠ°Π·Π»ΠΈΡΠ½ΡΠΌ ΡΠ΅Π½ΠΎΡΠΈΠΏΠΎΠΌ Π°ΡΠ΅ΡΠΈΠ»ΠΈΡΠΎΠ²Π°Π½ΠΈΡ ΠΏΡΠΈ Π½ΠΎΡΠΌΠ°Π»ΠΈΠ·ΠΎΠ²Π°Π½Π½ΠΎΠΌ Π²Π½ΡΡΡΠΈΠ³Π»Π°Π·Π½ΠΎΠΌ Π΄Π°Π²Π»Π΅Π½ΠΈΠΈ
PURPOSE: To study the character of clinical manifestations of ocular burns in patients with normal IOP and different acetylation phenotypes (APh).METHODS: We examined 103 patients with ocular burns (141 eyes) during their primary visit to the Republican Clinical Eye Hospital of the Ministry of Health of Uzbekistan, on different time-points during therapy (on days 2, 5, 7, 12 after the beginning of treatment) and then during an active clinical examination 30 days and 4 months after discharge. 44 patients were examined 1-2 years after suffering a burn injury in order to identify the later post-burn complications and their interpretation according to the patientβs APh. 52 (69 eyes) patients out of 103 examined patients (141 affected eyes) had a slow acetylation phenotype (SA) and 51 patients (72 eyes) β a fast acetylation phenotype (FA).RESULTS: The results of these studies allow us to assert that patients with SA phenotype develop deeper ocular burns, with eye tissue damages less prone to treatment than in FA patients, where less pronounced changes lead to faster process normalization. APh determines the course of the manifestations, their severity and risk of complications in ocular burns patients. Fast acetylation phenotype may serve as a prognostic marker of faster pathological changes regression in ocular tissues, whereas the slow acetylation phenotype suggests the development of more severe disease forms, often requiring a prolonged and complex therapy.Β Π¦ΠΠΠ¬. ΠΠ·ΡΡΠΈΡΡ Ρ
Π°ΡΠ°ΠΊΡΠ΅Ρ ΠΊΠ»ΠΈΠ½ΠΈΡΠ΅ΡΠΊΠΎΠ³ΠΎ ΡΠ΅ΡΠ΅Π½ΠΈΡ ΠΏΠΎΡΠ°ΠΆΠ΅Π½ΠΈΡ Π³Π»Π°Π·Π° ΠΏΡΠΈ Ρ
ΠΈΠΌΠΈΡΠ΅ΡΠΊΠΈΡ
ΠΎΠΆΠΎΠ³Π°Ρ
Π² Π·Π°Π²ΠΈΡΠΈΠΌΠΎΡΡΠΈ ΠΎΡ ΡΠ΅Π½ΠΎΡΠΈΠΏΠ° Π°ΡΠ΅ΡΠΈΠ»ΠΈΡΠΎΠ²Π°Π½ΠΈΡ (Π€Π) ΠΏΡΠΈ Π½ΠΎΡΠΌΠ°Π»ΠΈΠ·ΠΎΠ²Π°Π½Π½ΠΎΠΌ Π²Π½ΡΡΡΠΈΠ³Π»Π°Π·Π½ΠΎΠΌ Π΄Π°Π²Π»Π΅Π½ΠΈΠΈ (ΠΠΠ).ΠΠΠ’ΠΠΠ«. ΠΡΠ»ΠΈ ΠΎΠ±ΡΠ»Π΅Π΄ΠΎΠ²Π°Π½Ρ 103 Π±ΠΎΠ»ΡΠ½ΡΡ
Ρ ΠΎΠΆΠΎΠ³Π°ΠΌΠΈ Π³Π»Π°Π· (141 Π³Π»Π°Π·): ΠΏΡΠΈ ΠΏΠ΅ΡΠ²ΠΈΡΠ½ΠΎΠΌ ΠΎΠ±ΡΠ°ΡΠ΅Π½ΠΈΠΈ, Π½Π° ΡΡΠ°ΠΏΠ°Ρ
ΡΠ΅ΡΠ°ΠΏΠΈΠΈ (2, 5, 7, 12 ΡΡΡΠΊΠΈ ΠΎΡ ΠΌΠΎΠΌΠ΅Π½ΡΠ° ΠΎΠ±ΡΠ°ΡΠ΅Π½ΠΈΡ Π² ΠΊΠ»ΠΈΠ½ΠΈΠΊΡ) ΠΈ ΠΏΡΠΈ Π°ΠΊΡΠΈΠ²Π½ΠΎΠΉ Π΄ΠΈΡΠΏΠ°Π½ΡΠ΅ΡΠΈΠ·Π°ΡΠΈΠΈ Π² ΡΡΠΎΠΊΠΈ 30 Π΄Π½Π΅ΠΉ ΠΈ 4 ΠΌΠ΅Ρ. ΠΏΠΎΡΠ»Π΅ Π²ΡΠΏΠΈΡΠΊΠΈ. Π§Π΅ΡΠ΅Π· 1-2 Π³ΠΎΠ΄Π° ΠΏΠΎΡΠ»Π΅ ΠΏΠ΅ΡΠ΅Π½Π΅ΡΠ΅Π½Π½ΠΎΠΉ ΠΎΠΆΠΎΠ³ΠΎΠ²ΠΎΠΉ ΡΡΠ°Π²ΠΌΡ Ρ ΡΠ΅Π»ΡΡ Π²ΡΡΠ²Π»Π΅Π½ΠΈΡ ΠΏΠΎΠ·Π΄Π½ΠΈΡ
ΠΏΠΎΡΠ»Π΅ΠΎΠΆΠΎΠ³ΠΎΠ²ΡΡ
ΠΎΡΠ»ΠΎΠΆΠ½Π΅Π½ΠΈΠΉ ΠΈ ΠΈΡ
ΠΈΠ½ΡΠ΅ΡΠΏΡΠ΅ΡΠ°ΡΠΈΠΈ Ρ ΡΡΠ΅ΡΠΎΠΌ Π€Π ΡΠ°ΠΊΠΆΠ΅ Π±ΡΠ»ΠΈ ΠΎΠ±ΡΠ»Π΅Π΄ΠΎΠ²Π°Π½Ρ 44 ΠΏΠ°ΡΠΈΠ΅Π½ΡΠ°. ΠΠ· ΠΎΠ±ΡΠ΅Π³ΠΎ ΡΠΈΡΠ»Π° 103 ΠΎΠ±ΡΠ»Π΅Π΄ΠΎΠ²Π°Π½Π½ΡΡ
Π»ΠΈΡ (141 ΠΏΠΎΡΠ°ΠΆΠ΅Π½Π½ΡΠΉ Π³Π»Π°Π·) β 52 (69 Π³Π»Π°Π·) Π±ΠΎΠ»ΡΠ½ΡΡ
Π±ΡΠ»ΠΈ Ρ ΠΌΠ΅Π΄Π»Π΅Π½Π½ΡΠΌ ΡΠΈΠΏΠΎΠΌ ΡΠ΅Π½ΠΎΡΠΈΠΏΠ° Π°ΡΠ΅ΡΠΈΠ»ΠΈΡΠΎΠ²Π°Π½ΠΈΡ (ΠΠ) ΠΈ 51 Π±ΠΎΠ»ΡΠ½ΠΎΠΉ (72 Π³Π»Π°Π·Π°) β Ρ Π±ΡΡΡΡΡΠΌ ΡΠΈΠΏΠΎΠΌ Π°ΡΠ΅ΡΠΈΠ»ΠΈΡΠΎΠ²Π°Π½ΠΈΡ (ΠΠ).Π ΠΠΠ£ΠΠ¬Π’ΠΠ’Π«. Π Π΅Π·ΡΠ»ΡΡΠ°ΡΡ ΠΏΡΠΎΠ²Π΅Π΄Π΅Π½Π½ΡΡ
ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΠΉ ΠΏΠΎΠ·Π²ΠΎΠ»ΡΡΡ ΡΡΠ²Π΅ΡΠΆΠ΄Π°ΡΡ, ΡΡΠΎ ΠΏΡΠΈ ΠΎΠΆΠΎΠ³Π°Ρ
Π³Π»Π°Π· ΠΏΡΠΈ ΠΠ ΡΠ°Π·Π²ΠΈΠ²Π°ΡΡΡΡ Π±ΠΎΠ»Π΅Π΅ Π³Π»ΡΠ±ΠΎΠΊΠΈΠ΅, ΡΡΠΆΠ΅Π»ΠΎ ΠΏΠΎΠ΄Π΄Π°ΡΡΠΈΠ΅ΡΡ Π»Π΅ΡΠ΅Π½ΠΈΡ Π΄Π΅ΡΡΡΡΠΊΡΠΈΠ²Π½ΡΠ΅ Π½Π°ΡΡΡΠ΅Π½ΠΈΡ Π² ΡΠΊΠ°Π½ΡΡ
Π³Π»Π°Π·Π°, ΠΏΡΠΈ ΠΠ β ΠΌΠ΅Π½Π΅Π΅ Π²ΡΡΠ°ΠΆΠ΅Π½Π½ΡΠ΅ ΠΈΠ·ΠΌΠ΅Π½Π΅Π½ΠΈΡ, ΠΊΠΎΡΠΎΡΡΠ΅ Π² Π΄Π°Π»ΡΠ½Π΅ΠΉΡΠ΅ΠΌ Π±ΡΡΡΡΠ΅Π΅ ΠΏΡΠΈΠ²ΠΎΠ΄ΡΡ ΠΊ Π½ΠΎΡΠΌΠ°Π»ΠΈΠ·Π°ΡΠΈΠΈ ΠΏΡΠΎΡΠ΅ΡΡΠ°. Π€Π ΠΎΠΏΡΠ΅Π΄Π΅Π»ΡΠ΅Ρ Ρ
Π°ΡΠ°ΠΊΡΠ΅Ρ ΡΠ΅ΡΠ΅Π½ΠΈΡ, ΡΡΠΆΠ΅ΡΡΡ ΠΈ ΡΠΈΡΠΊ ΡΠ°Π·Π²ΠΈΡΠΈΡ ΠΎΡΠ»ΠΎΠΆΠ½Π΅Π½ΠΈΠΉ ΠΏΡΠΈ ΠΎΠΆΠΎΠ³Π°Ρ
Π³Π»Π°Π·. ΠΠ ΠΌΠΎΠΆΠ΅Ρ ΡΠ»ΡΠΆΠΈΡΡ ΠΏΡΠΎΠ³Π½ΠΎΡΡΠΈΡΠ΅ΡΠΊΠΈΠΌ ΠΌΠ°ΡΠΊΠ΅ΡΠΎΠΌ ΠΊ Π±ΠΎΠ»Π΅Π΅ Π±ΡΡΡΡΠΎΠΉ ΡΠ΅Π³ΡΠ΅ΡΡΠΈΠΈ ΠΏΠ°ΡΠΎΠ»ΠΎΠ³ΠΈΡΠ΅ΡΠΊΠΈΡ
ΠΈΠ·ΠΌΠ΅Π½Π΅Π½ΠΈΠΉ Π² ΡΠΊΠ°Π½ΡΡ
Π³Π»Π°Π·Π°, ΠΠ ΠΏΡΠ΅Π΄ΠΏΠΎΠ»Π°Π³Π°Π΅Ρ ΠΊ ΡΠ°Π·Π²ΠΈΡΠΈΡ Π±ΠΎΠ»Π΅Π΅ ΡΡΠΆΠ΅Π»ΡΡ
ΡΠΎΡΠΌ Ρ Π·Π°ΡΡΠΆΠ½ΡΠΌ ΠΈ ΠΎΡΠ»ΠΎΠΆΠ½Π΅Π½Π½ΡΠΌ ΡΠ΅ΡΠ΅Π½ΠΈΠ΅ΠΌ, ΡΡΡΠ΄Π½ΠΎ ΠΏΠΎΠ΄Π΄Π°ΡΡΠΈΡ
ΡΡ ΡΡΠ°Π΄ΠΈΡΠΈΠΎΠ½Π½ΠΎΠΉ ΡΠ΅ΡΠ°ΠΏΠΈΠΈ.
ΠΠ΅ΠΉΡΠΎΠ±ΠΈΠΎΡ ΠΈΠΌΠΈΡΠ΅ΡΠΊΠΈΠ΅ ΠΊΡΠΈΡΠ΅ΡΠΈΠΈ Π΄ΠΈΠ°Π³Π½ΠΎΡΡΠΈΠΊΠΈ Π³Π»Π°Π·Π½ΠΎΠ³ΠΎ ΠΈΡΠ΅ΠΌΠΈΡΠ΅ΡΠΊΠΎΠ³ΠΎ ΡΠΈΠ½Π΄ΡΠΎΠΌΠ°
PURPOSE: To investigate abnormalities of neurospecific protein S-100 level in patients with ocular ischemic syndrome. METHODS: The material included 28 people aged 59 to 79 years. Control group consisted of 10 volunteers without ophthalmic symptoms, main group (Group 2) consisted of 18 patients with ocular ischemic syndrome. Neurospecific protein level was determined by means of chemiluminescence immunoassay in blood serum and lacrimal fluid by an automatic electrochemiluminescence immunoassay analyzer Cobas e 411 (Β«Roche DiagnosticsΒ», Switzerland). The amount of protein in the fluid up to 0.105 mmol/l was considered a normal value. RESULTS: The study established that the levels of S-100 in the control group were 0.0914Β±0.0012 mmol/l in lacrimal fluid and 0.0712Β±0.0021 mmol/l in blood serum, which was within normal range. In the main group lacrimal levels of S-100 protein were increased in 18 patients and averaged 5.871Β±0.027 mmol/l (pΠ¦ΠΠΠ¬. ΠΠ·ΡΡΠ΅Π½ΠΈΠ΅ Π½Π°ΡΡΡΠ΅Π½ΠΈΡ ΡΡΠΎΠ²Π½Ρ Π½Π΅ΠΉΡΠΎΡΠΏΠ΅ΡΠΈΡΠΈΡΠ΅ΡΠΊΠΎΠ³ΠΎ Π±Π΅Π»ΠΊΠ° S-100 ΠΏΡΠΈ Π³Π»Π°Π·Π½ΠΎΠΌ ΠΈΡΠ΅ΠΌΠΈΡΠ΅ΡΠΊΠΎΠΌ ΡΠΈΠ½Π΄ΡΠΎΠΌΠ΅ (ΠΠΠ‘). ΠΠΠ’ΠΠΠ«. ΠΠ°ΡΠ΅ΡΠΈΠ°Π»ΠΎΠΌ ΠΏΠΎΡΠ»ΡΠΆΠΈΠ»ΠΈ Π΄Π°Π½Π½ΡΠ΅ 28 ΡΠ΅Π»ΠΎΠ²Π΅ΠΊ Π² Π²ΠΎΠ·ΡΠ°ΡΡΠ΅ ΠΎΡ 59 Π΄ΠΎ 79 Π»Π΅Ρ. ΠΠΎΠ½ΡΡΠΎΠ»ΡΠ½ΡΡ Π³ΡΡΠΏΠΏΡ ΡΠΎΡΡΠ°Π²ΠΈΠ»ΠΈ 10 Π΄ΠΎΠ±ΡΠΎΠ²ΠΎΠ»ΡΡΠ΅Π² Π±Π΅Π· ΠΎΡΡΠ°Π»ΡΠΌΠΎΠ»ΠΎΠ³ΠΈΡΠ΅ΡΠΊΠΎΠΉ ΡΠΈΠΌΠΏΡΠΎΠΌΠ°ΡΠΈΠΊΠΈ, ΠΎΡΠ½ΠΎΠ²Π½Π°Ρ Π³ΡΡΠΏΠΏΠ° (2 Π³ΡΡΠΏΠΏΠ°) ΡΠΎΡΡΠΎΡΠ»Π° ΠΈΠ· 18 ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΎΠ² Ρ ΠΠΠ‘. ΠΠΎΠ»ΠΈΡΠ΅ΡΡΠ²ΠΎ Π½Π΅ΠΉΡΠΎΡΠΏΠ΅ΡΠΈΡΠΈΡΠ΅ΡΠΊΠΎΠ³ΠΎ Π±Π΅Π»ΠΊΠ° ΠΎΠΏΡΠ΅Π΄Π΅Π»ΡΠ»ΠΎΡΡ Ρ ΠΏΠΎΠΌΠΎΡΡΡ Ρ
Π΅ΠΌΠΈΠ»ΡΠΌΠΈΠ½Π΅ΡΡΠ΅Π½ΡΠ½ΠΎΠ³ΠΎ ΠΈΠΌΠΌΡΠ½ΠΎΠ°Π½Π°Π»ΠΈΠ·Π° Π² ΡΡΠ²ΠΎΡΠΎΡΠΊΠ΅ ΠΊΡΠΎΠ²ΠΈ (Π‘Π) ΠΈ ΡΠ»Π΅Π·Π½ΠΎΠΉ ΠΆΠΈΠ΄ΠΊΠΎΡΡΠΈ (Π‘Π) Π½Π° Π°Π²ΡΠΎΠΌΠ°ΡΠΈΡΠ΅ΡΠΊΠΎΠΌ ΡΠ»Π΅ΠΊΡΡΠΎΡ
Π΅ΠΌΠΈΠ»ΡΠΌΠΈΠ½Π΅ΡΡΠ΅Π½ΡΠ½ΠΎΠΌ ΠΈΠΌΠΌΡΠ½ΠΎΠ°Π½Π°Π»ΠΈΠ·Π°ΡΠΎΡΠ΅ Cobas e 411 (Β«Roche DiagnosticsΒ», Π¨Π²Π΅ΠΉΡΠ°ΡΠΈΡ). ΠΠΎΡΠΌΠ°Π»ΡΠ½ΡΠΌΠΈ ΠΏΠΎΠΊΠ°Π·Π°ΡΠ΅Π»ΡΠΌΠΈ ΡΡΠΈΡΠ°Π»ΠΈ ΠΊΠΎΠ»ΠΈΡΠ΅ΡΡΠ²ΠΎ Π±Π΅Π»ΠΊΠ° Π² ΠΆΠΈΠ΄ΠΊΠΎΡΡΠΈ Π΄ΠΎ 0,105 ΠΌΠΌΠΎΠ»Ρ/Π». Π ΠΠΠ£ΠΠ¬Π’ΠΠ’Π«. ΠΠΎ ΡΠ΅Π·ΡΠ»ΡΡΠ°ΡΠ°ΠΌ ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΡ Π±ΡΠ»ΠΎ Π²ΡΡΠ²Π»Π΅Π½ΠΎ, ΡΡΠΎ Ρ Π±ΠΎΠ»ΡΠ½ΡΡ
ΠΊΠΎΠ½ΡΡΠΎΠ»ΡΠ½ΠΎΠΉ Π³ΡΡΠΏΠΏΡ ΠΏΠΎΠΊΠ°Π·Π°ΡΠ΅Π»ΠΈ Π±Π΅Π»ΠΊΠ° S-100 Π² Π‘Π ΡΠΎΡΡΠ°Π²ΠΈΠ»ΠΈ 0,0914Β±0,0012 ΠΌΠΌΠΎΠ»Ρ/Π», Π² Π‘Π - 0,0712Β±0,0021 ΠΌΠΌΠΎΠ»Ρ/Π», ΡΡΠΎ Π±ΡΠ»ΠΎ Π² ΠΏΡΠ΅Π΄Π΅Π»Π°Ρ
Π½ΠΎΡΠΌΡ. Π£ Π±ΠΎΠ»ΡΠ½ΡΡ
ΠΎΡΠ½ΠΎΠ²Π½ΠΎΠΉ Π³ΡΡΠΏΠΏΡ ΠΏΠΎΠΊΠ°Π·Π°ΡΠ΅Π»ΠΈ Π΄Π°Π½Π½ΠΎΠ³ΠΎ Π±Π΅Π»ΠΊΠ° Π² Π‘Π Π±ΡΠ»ΠΈ ΠΏΠΎΠ²ΡΡΠ΅Π½Ρ Ρ Π²ΡΠ΅Ρ
Π±ΠΎΠ»ΡΠ½ΡΡ
ΠΈ ΡΠΎΡΡΠ°Π²ΠΈΠ»ΠΈ Π² ΡΡΠ΅Π΄Π½Π΅ΠΌ 5,871Β±0,027 ΠΌΠΌΠΎΠ»Ρ/Π» (
Effect of structural defects on anomalous ultrasound propagation in solids during second-order phase transitions
The effect of structural defects on the critical ultrasound attenuation and
ultrasound velocity dispersion in Ising-like three-dimensional systems is
studied. A field-theoretical description of the dynamic effects of
acoustic-wave propagation in solids during phase transitions is performed with
allowance for both fluctuation and relaxation attenuation mechanisms. The
temperature and frequency dependences of the scaling functions of the
attenuation coefficient and the ultrasound velocity dispersion are calculated
in a two-loop approximation for pure and structurally disordered systems, and
their asymptotic behavior in hydrodynamic and critical regions is separated. As
compared to a pure system, the presence of structural defects in it is shown to
cause a stronger increase in the sound attenuation coefficient and the sound
velocity dispersion even in the hydrodynamic region as the critical temperature
is reached. As compared to pure analogs, structurally disordered systems should
exhibit stronger temperature and frequency dependences of the acoustic
characteristics in the critical region.Comment: 7 RevTeX pages, 4 figure
Effect of Preheating on Mechanical Properties of Different Commercially Available Dental Resin Composites
Background: This study aimed to reveal the effect of preheating on the surface microhardness and shear strength of composite materials used in the restoration of posterior teeth.
Methods and Results: There were 3 composite materials under the study: Estelite Posterior, Harmonize and Filtek Z550. To make static and dynamic tests of them, 120 filling samples were prepared. Of those, 60 samples were for surface hardness measurements and 60 samples were used to evaluate the shear strength of composite materials. We formed 12 study groups with 10 filling samples in each. Samples made off Estelite Posterior, Harmonizeβ’, and Filtekβ’ were designated with E, H, and F capital letters, respectively; the "VH" abbreviation indicated static Vickers hardness testing and "SS" was assigned for dynamic shear testing; mark (Β°) was used when preheating was applied. Filling samples were made of heated (up to 60Β°C) and room-temperature (23-25Β°C) composite materials. The filling samples of EVH, EΒΊVH, HVH, HΒΊVH, FVH, and FΒΊVH groups were subjected to a surface microhardness test. The samples of ESS, EΒΊSS, HSS, HΒΊSS, FSS, and FΒΊSS groups were subjected to shear-strength assessment of materials. The surface microhardness of filling samples was measured using a ΠMT-3 Vickers hardness tester and the Vickers hardness number (VHN) was calculated. Dynamic tests were carried out using an UltraTester machine (Ultradent, Inc., USA) and shear test method until the shear-strength (SS) filling sample had completely failed.
After analysis of the obtained results, it was found that preheating had enhanced the surface hardness and mechanical strength of the composite materials used in the study. However, the positive influence of preheating was significant only in the EVH-EΒΊVH, ESS-EΒΊSS, HSS-HΒΊSS, and FSS-FΒΊSS groups in 1.21, 1.09, 1.33, and 1.16 times, respectively. In the HVH-HΒΊVH and FVH-FΒΊVH groups, the identified differences were not of significance despite the improvement in mean values at 1.08 and 1.1 times.
Conclusion: Preheating of light-curing resin-based composites is not equally effective for static and dynamic mechanical properties of materials for dental restoration. Preliminary laboratory tests could have helped before their clinical use
SPECIFIC MARKER OF NEURODEGENERATION IN OPTIC NEURITIS DIAGNOSING
Aim. To assess prognostic value of neuron-specific enolase (NSE) in blood serum and tear fluid in optic neuritis (ON).Patients and methods. ON patients as well as healthy persons were examined. Group I included 27 patients (27 eyes) with acute ON. Group II included 23 patients (23 eyes) with ON and continuing optic nerve atrophy. Group III (controls) included 10 healthy persons (20 eyes). NSE levels in tear fluid and blood serum were measured using electrochemical luminescence immune analyzer Cobas-e-411.Results. In group I, NSE levels in tear fluid and blood serum averaged 0.81Β±0.15 and 13.67Β±1.44 ng/mL, respectively. In group II, NSE level in tear fluid was 24.86Β±3.84 ng/mL (on average) while its blood serum level was within normal limits. In controls, NSE levels in tear fluid and blood serum were within normal limits (15.7Β±0.2 and 16.8Β±0.12 ng/mL, respectively).Conclusions. In group I, NSE level in tear fluid was 19βfold less than normal (Ρ < 0.05). It appears to be due to the activation of hypoxia and anaerobic glycolysis in neurons. In group II, NSE level in tear fluid was 1.43βfold higher than normal (Ρ < 0.05). This may be due to neuronal degeneration and progressive death with NSE release from damaged neurons into the cellular matrix
ESTIMATION OF EFFICIENCY OF COMPLEX TREATMENT OF OPTIC NEURITIS BY MAGNETIC RESONANCE TRACTOGRAPHY
Purpose. To study the efficacy of complex treatment for optic neuritis using neuroprotectors according to magnetic resonance (MR) tractography findings.Material and methods. The study included 23 patients (31 eyes) with optic neuritis. They were divided into two groups of patients depending on the type of treatment. The control group consisted of 11 patients (15 eyes), who received a standard conservative therapy: anti-inflammatory, decongestants, desensitizing therapy. The patients of the main group (12 patients, 16 eyes) in addition to the above complex, received Cerebrolysin intravenously 10.0ml in 10ml of saline solution during 10 days, then Gliatilin (choline alfoscerate) in tablets 0.4gr 3 times per day for 2 months. The standard ophthalmic methods and special investigation methods were performed in all patients. The MR tractography was carried out using the magnetic resonance imaging BRIVO-355/1.5 Tesla GE (USA).Results. On admission to the hospital the visual acuity of the patients in both groups averaged 0.23Β±0.14, the total limit of visual field (TLVF) was mean 324.0Β±6.8Ρ. As a result of performed therapy the main group of patients showed an increase in visual acuity up to 0.59Β±0.05 (p<0.05). In the control group the visual acuity was 0.38Β±0.04, which although were higher than basic data, but not statistically authentic. In the control group, the TLVF 1 month after the treatment increased in comparison with the initial data 1.17 times and was mean 382.4Β±7.2Ρ. Dynamics of indices of the TLVF in the main group 1 month after the combined treatment with neuroprotectors showed an mean improvement 48.2Β±6.4Ρ (increase of 1.54 times). After the performed therapy in the control group 7 patients preserved thinning in fibers of optic radiation, some rupture of fiber filaments of occipital forceps at the site of attachment to optic radiation were observed in 3 patients. In the main group after the neuroprotective therapy the relationship of the fibers of the optic tract was restored in 8 patients. Thinned fibers of occipital forceps at the site of attachment to the optic radiation was visualized within the norm after the treatment.Conclusion. 1. Method of magnetic resonance tractography allows to visualize non-invasively pathways of white matter and to assess an extent of their damage in inflammatory diseases of the optic nerve and tract. Changes on the MR tractography images indicate a damage in fibers from the optic tracts to the optic radiation, reflecting the degree of damage in different levels of the visual system. 2. Changes on MR tractography images in patients with optic neuritis can serve as objective criteria to evaluate the efficacy of the treatment method
Comparative Analysis of in vitro Performance of Total-Etch and Self-Etch Adhesives
The aim of the study was in vitro assessment of shear bond strength and micro-leakage after application of total-etch and self-etch adhesive systems.
Materials and Methods: Four adhesive systems were chosen for assessment of adhesion performance: Contax (DMG, GmbH), Bond Force (Tokuyama Dental Corp. Japan Mfr), Te-Econom Bond (Ivoclar Vivadent, Liechtenstein) and Swisstec SL Bond (Coltene, Switzerland). The assessment of bond strength was performed on 20 tooth samples, which were prepared in accordance with the UltraTest technique for shear bond strength (SBS) estimation. The test was conducted at a crosshead speed of 1.0 mm/min and results were fixed in kilograms. The assessment of SBS was performed on enamel and dentin separately. Microleakage assessment of self-etch and total-etch adhesive systems was performed on 20 extracted non-carious upper human premolars with immersion in 1% methylene blue solution after thermocycling.
Results: Good SBS results and microleakage values on the dentin substrate were obtained after application of the Contax self-etch bonding agent. But the values of bond strength to enamel and the extent of dye penetration within the composite-enamel interface were still better with the total-etch approach